Agile Therapeutics Inc (AGRX) Stock Price, Quote & News

Profitrip May. 28 at 8:58 AM

$SGBX shorted the pop / not $AGRX type o

0 · Reply

Profitrip May. 28 at 8:33 AM

$AGRX ss the pop

0 · Reply

JasonCO May. 9 at 6:42 PM

$AGRX on watch

0 · Reply

JMJTrading May. 2 at 2:50 PM

$BLMZ Unbelievable setup here, the fueling is unreal, 30's soon! $ELOX $AGRX

0 · Reply

Best4yourbuck Mar. 24 at 10:34 AM

$AGRX f this stock lost so much in this

0 · Reply

Stock_Guy_69 Feb. 24 at 9:04 PM

$AGRX $SENS So blessed! 🤣

1 · Reply

dln101 Feb. 6 at 1:35 PM

$AVGR depending on where it opens may get some for a bounce 🤔 $AGRX 🔥📈

1 · Reply

NVDAistheSHIZ Feb. 4 at 2:23 PM

$CODX $AGRX https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-1-for-100-reverse-stock-py8xwkged9yd.html This is the type of BS that happens in the drug world...don't invest in this sector...never

1 · Reply

NVDAMillionaire Jan. 25 at 3:00 PM

$AGRX Agile Therapeutics, Inc. (AGRX): Executing on Commercialization Strategy, Poised for Continued Growth https://beyondspx.com/article/agile-therapeutics-inc-agrx-executing-on-commercialization-strategy-poised-for-continued-growth

0 · Reply

CanadianApe69 Jan. 23 at 4:42 PM

$DWTX $AGRX and $HOTH

0 · Reply

Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.

Aug 7, 2024, 4:22 AM EDT - 11 months ago

Agile Leadership for Pharma and Biopharma Professionals in a Hybrid World: 2-Day Training Course (Online) November 18-19, 2024 - Become Competent and Familiar in a Range of Well-Recognised Leadership Techniques

Jun 28, 2024, 6:14 PM EDT - 1 year ago

AGILE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Agile Therapeutics, Inc. - AGRX

Jun 26, 2024, 7:45 AM EDT - 1 year ago

Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.

May 15, 2024, 4:10 PM EDT - 1 year ago

Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 28, 2024, 10:46 AM EDT - 1 year ago

Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 8:05 AM EDT - 1 year ago

Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update

Mar 25, 2024, 4:30 PM EDT - 1 year ago

Agile Therapeutics Announces Delisting from Nasdaq

Mar 21, 2024, 6:35 AM EDT - 1 year ago

Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024

Mar 20, 2024, 8:15 AM EDT - 1 year ago

Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024

Mar 13, 2024, 7:31 AM EDT - 1 year ago

Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution

Feb 22, 2024, 9:01 AM EST - 1 year ago

Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds

Feb 15, 2024, 4:30 PM EST - 1 year ago

Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement & Provides Performance Update

Jan 23, 2024, 9:29 AM EST - 1 year ago

The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost

Dec 12, 2023, 8:01 AM EST - 1 year ago

Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act's No-Cost Contraceptive Coverage Requirement

Nov 22, 2023, 9:00 AM EST - 1 year ago

Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024

Nov 9, 2023, 1:14 PM EST - 1 year ago

Agile Therapeutics, Inc. (AGRX) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 8:05 AM EST - 1 year ago

Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 26, 2023, 8:05 AM EDT - 1 year ago

Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023

Oct 4, 2023, 4:30 PM EDT - 1 year ago

Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Sep 28, 2023, 9:00 AM EDT - 1 year ago

Agile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim Group

Sep 5, 2023, 8:05 AM EDT - 1 year ago

Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 9:00 AM EDT - 2 years ago

Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter

Aug 9, 2023, 8:05 AM EDT - 2 years ago

Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 26, 2023, 8:30 AM EDT - 2 years ago

Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023

Jul 19, 2023, 9:00 AM EDT - 2 years ago

This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys

Jul 11, 2023, 9:15 AM EDT - 2 years ago

Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden's Latest Executive Order Expanding Contraceptive Coverage

Jul 5, 2023, 9:00 AM EDT - 2 years ago

H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch

Jul 3, 2023, 9:00 AM EDT - 2 years ago

This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023

Jun 30, 2023, 9:00 AM EDT - 2 years ago

Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 - What Is The Hype All About?

Jun 26, 2023, 8:01 AM EDT - 2 years ago

Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members

Jun 23, 2023, 12:05 PM EDT - 2 years ago

Agile Therapeutics Commends the Biden Administration's Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services

Jun 15, 2023, 4:05 PM EDT - 2 years ago

Agile Therapeutics Announces the Availability of Twirla® through FPA Women's Health

Jun 13, 2023, 4:05 PM EDT - 2 years ago

Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®

May 25, 2023, 4:05 PM EDT - 2 years ago

Agile Therapeutics Announces Closing of $7.5 Million Public Offering

May 22, 2023, 8:00 PM EDT - 2 years ago

Agile Therapeutics Announces Pricing of $7.5 Million Public Offering

May 12, 2023, 7:09 PM EDT - 2 years ago

Agile Therapeutics, Inc. (AGRX) Q1 2023 Earnings Call Transcript

May 11, 2023, 4:05 PM EDT - 2 years ago

Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update

May 8, 2023, 8:00 AM EDT - 2 years ago

Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023

Apr 28, 2023, 8:01 AM EDT - 2 years ago

Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023

Apr 26, 2023, 9:01 AM EDT - 2 years ago

Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Apr 10, 2023, 4:30 PM EDT - 2 years ago

Agile Therapeutics Announces 1-For-50 Reverse Stock Split

Mar 24, 2023, 12:31 PM EDT - 2 years ago

Agile Therapeutics, Inc (AGRX) Q4 2022 Earnings Call Transcript

Mar 22, 2023, 4:05 PM EDT - 2 years ago

Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update

Mar 21, 2023, 9:05 AM EDT - 2 years ago

Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023

Feb 27, 2023, 8:31 AM EST - 2 years ago

Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

Feb 15, 2023, 8:00 AM EST - 2 years ago

Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial Officer

Feb 9, 2023, 8:00 AM EST - 2 years ago

Corium Pharma Solutions Names Two Industry Veterans to its Executive Team

Feb 1, 2023, 8:01 AM EST - 2 years ago

Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation

Profitrip May. 28 at 8:58 AM

$SGBX shorted the pop / not $AGRX type o

0 · Reply

Profitrip May. 28 at 8:33 AM

$AGRX ss the pop

0 · Reply

JasonCO May. 9 at 6:42 PM

$AGRX on watch

0 · Reply

JMJTrading May. 2 at 2:50 PM

$BLMZ Unbelievable setup here, the fueling is unreal, 30's soon! $ELOX $AGRX

0 · Reply

Best4yourbuck Mar. 24 at 10:34 AM

$AGRX f this stock lost so much in this

0 · Reply

Stock_Guy_69 Feb. 24 at 9:04 PM

$AGRX $SENS So blessed! 🤣

1 · Reply

dln101 Feb. 6 at 1:35 PM

$AVGR depending on where it opens may get some for a bounce 🤔 $AGRX 🔥📈

1 · Reply

NVDAistheSHIZ Feb. 4 at 2:23 PM

1 · Reply

NVDAMillionaire Jan. 25 at 3:00 PM

0 · Reply

CanadianApe69 Jan. 23 at 4:42 PM

$DWTX $AGRX and $HOTH

0 · Reply

Morgo Dec. 23 at 2:20 PM

$AGRX 👀

0 · Reply

_802016493_ Dec. 17 at 2:16 AM

$INTC if they name a guy name Al Altomari as CEO I'll be 100% out that second ($AGRX)

1 · Reply

wd122 Nov. 23 at 7:49 PM

$AGRX put all my agrx profits into $WVTRS.X . Big things coming in 2025.

1 · Reply

Manjunk Nov. 5 at 4:38 AM

$AGRX how's Super Mario these days 🫣

1 · Reply

stkmkt Oct. 22 at 5:18 PM

$AGRX just saw in GMA news... Biden administration expanding birth control acess... too bad $AGRX couldn't take advantage of programs like this.

1 · Reply

Jeff123123 Oct. 3 at 4:36 PM

$AGRX Demons, pay 3000 times or More or go to HELL forever.

0 · Reply

Gettingpaid2021 Sep. 30 at 1:35 AM

$AGRX $67,000 invest to be paid $728. Fuck AL

3 · Reply

glove_33 Sep. 24 at 1:34 PM

$AGRX Good riddens. I’ve been bashing the hell out of this POS for years after getting suckered in myself. What was interesting is that the Bulls wouldn’t listen to a single Bearish rational comment. They would justify, make excuses, and keep buying at every new all time low all the way to the bottom of the never ending cesspool. Happy this is my last bearish post on this garbage before I formally said good buy and delete this clown of a ticker off my watchlist. It was an expensive lesson.

1 · Reply

glove_33 Sep. 24 at 1:30 PM

$AGRX As of August 2024, Agile Therapeutics (AGRX) is no longer publicly traded. The company was acquired by Insud Pharma, a global pharmaceutical group, in a deal valued at approximately $45 million. As part of the acquisition, shareholders of Agile Therapeutics received $1.52 per share. After the transaction, Agile merged with Exeltis USA (a subsidiary of Insud), and the company has been delisted from public markets, including the OTCQB

0 · Reply

Billno Sep. 5 at 2:59 PM

$AGRX Wow ! Is all I can Say ! Once again the,VOTE OF SHAREHOLDERS , Meant Nothing and Destroyed Shareholder Value so bod ,and Market makers, and predatory Hedgefunds can profit off the Backs of Retail. All While GARY GENSLER, @Sec .turns his head , takes his cut, tells everyone OH No ! Everything's GREAT.

1 · Reply

bigshepherdd Sep. 2 at 11:07 PM

$AGRX GME🟢GME🤑GME🤑🤑GME

0 · Reply

GansoManso Sep. 1 at 6:21 AM

$AGRX The mafia broker banks are illegally allowing the use of counterfeit shares so that their hedge fund buddies (another division of the same parasitic entity) can steal retail investors' money, and the corrupt company executives are helping them do it with incessant reverse splits and deliberate dilution. "... this really should be front page news, but the banks and brokers have big marketing budgets, so i imagine there will be very little coverage on this important news for investors in North America." The SEC was created and is controlled by the mafia broker banks, so don't expect them to do anything. Musk aptly dubbed them the "Short-Sellers Enrichment Commission". The only way to win is to stop playing their game. Instead, invest in ammo... not the ticker. https://finance.yahoo.com/news/end-naked-short-selling-230100677.html?guce_referrer=aHR0cHM6Ly93d3cuYmluZy5jb20v&guce_referrer_sig=AQAAAEg4_ra_uhbMoBbyVjhIRSOJqSlvjmByE_BwR27RFFtzghYSYnV9THkf-j7qc_AwjgcoWD1euIBQWwGKdNUtBpSmzFu6TarMAnOdbh6t4UQ9Lm4ojf6uamskgwhQy4Ct-0gfx19CCq-8-aLzLZrY5Cd5bL9RAveuQ1NEMKWSttF0&_guc_consent_skip=1725146611

0 · Reply

Market Cap	10.35M
Revenue (ttm)	19.59M
Net Income (ttm)	-14.47M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	120,900
Avg Vol	178,234
Day's Range	N/A - N/A
Shares Out	6.86M
Stochastic %K	88%
Beta	1.58
Analysts	Strong Sell
Price Target	$12.00